Q1 2025 Earnings

May 2025





This presentation contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like "expects," "estimates," "anticipates," "may," "could," "believes," "feels," "plans," "intends," "outlook" or similar words or expressions, for example) which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec's Annual Report on Form 10-K for the year ended December 31, 2024 and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading "Risk Factors" in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



The information presented in this presentation includes financial measures that are not calculated or presented in accordance with Generally Accepted Accounting Principles in the United States (GAAP). These non-GAAP financial measures comprise adjusted EBITDA, income before income taxes excluding special items, net income excluding special items and related per share amounts together with net cash. Adjusted EBITDA is net income per our consolidated financial statements adjusted for the exclusion of interest income, net, income taxes, depreciation and amortization, foreign currency exchange gains, legacy costs of closed operations and adjustment to fair value of contingent consideration. Income before income taxes, net income and diluted EPS, excluding special items, per our consolidated financial statements are adjusted for the exclusion of amortization of acquired intangible assets, adjustment to fair value of contingent consideration, legacy costs of closed operations, foreign currency exchange gains and adjustment of income tax provisions. Net cash is cash and cash equivalents less total debt. The Company believes that such non-GAAP financial measures provide useful information to investors and may assist them in evaluating the Company's underlying performance and identifying operating trends. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors and the Company has determined that it is appropriate to make this data available to all investors. While the Company believes that such measures are useful in evaluating the Company's performance, investors should not consider them to be a substitute for financial measures prepared in accordance with GAAP. In addition, these non-GAAP financial measures may differ from similarly-titled non-GAAP financial measures used by other companies and do not provide a comparable view of the Company's performance relative to other companies in similar industries. Management uses adjusted EPS (the most directly comparable GAAP financial measure for which is GAAP EPS) and net income excluding special items and adjusted EBITDA (the most directly comparable GAAP financial measure for which is GAAP net income) to allocate resources and evaluate the performance of the Company's operations and has provided a reconciliation of adjusted EBITDA and net income excluding special items, and related per share amounts, to GAAP net income in our earnings release.



- 1 Introduction David Jones - VP, General Counsel
- 2 Business Commentary Patrick S. Williams - President & CEO
- 3 Financial Performance Ian Cleminson - Executive Vice President & CFO
- 4 Questions & Answers Patrick S. Williams and Ian Cleminson





GAAP EPS of \$1.31	Overall good results	Balance sheet has \$299.8 million in net cash
Adjusted non-GAAP EPS of \$1.42	Excellent growth in Fuels Specialties offsetting lower results in Performance Chemicals and Oilfield Services	10 percent semi-annual dividend increase; \$3.3 million in share repurchases
Performance Chemicals moderating activity in run-up to April 2nd	Fuel Specialties double- digit operating income growth with continued progress on margin	Oilfield Services continued strength in Middle East and DRA; lower results in US completions and
Near-term headwind on sequential growth; no change in long-term direction	improvement	production Cost management actions in process

Financial Performance



Q1 2025 Consolidated Results (\$ MM)





\$1.42


-19%

- Gross margin down 2.7 percentage points
- Operating income down 16 percent
- Adjusted EBITDA down 16 percent
- Adjusted EPS of \$1.42

[•] Revenue down 12 percent

Q1 2025 Performance Chemicals (\$ MM)


innospec




- Revenue up 5 percent
- Volumes up 5 percent
- Price/mix up 3 percent
- Gross margin down 2.4
 percentage points
- Operating income down 6 percent

Q1 2025 Fuel Specialties (\$ MM)

innospec






- Price/mix down 2 percent
- Gross margin up 1.4 percentage points
- Operating income up 10 percent

Q1 2025 Oilfield Services (\$ MM)


innospec



- Revenue down 37 percent
- No Latin America sales
- Gross margin down 6.9 percentage points on weaker sales mix
- Operating income down 76
 percent
- Future quarters will not show the comparable sharp declines from Latin America
- Cost management actions in process

Q1 2025 Corporate Items (\$ MM)






- Corporate costs down versus prior year on lower performancerelated remuneration
- Effective tax rate of 26.1 percent



Q1 2025 Balance Sheet (\$ MM)

innospec



Q1 2025

Q4 2024

- Operating cash inflow of \$28.3 million
- Capital expenditures of \$15.5
 million
- Net cash balance \$299.8 million

Concluding Comments





Summary of 1st Quarter Performance Good overall results; Benefiting from balanced business portfolio

Excellent growth in Fuels Specialties offsetting lower results in Performance Chemicals and Oilfield Services

Diversified supply-chain and regional manufacturing locations positioned to manage the direct impacts of global tariffs

Expect tariff uncertainty to delay sequential recovery in Performance Chemicals & Oilfield Services; Relative stability in Fuel Specialties

10 percent semi-annual dividend increase; \$3.3 million in share repurchases

\$300 million net cash on balance sheet to pursue further M&A, organic investment, dividend growth and share repurchases



©2025 Innospec Inc.



Final Comments

Thank You for Your Continued Support

August 2025							
Sun	Mon	Tue	Wed	Thu	Fri	Sat	
31					1	2	
3	4	5	6	7	8	9	
10	11	12	13	14	15	16	
17	18	19	20	21	22	23	
24	25	26	27	28	29	30	

Q2 2025 Results Schedule

- August 5th Results Release After Close
- August 6th Conference Call